Riboxin - instructions for use, dose, side effects, contraindications

Riboxin is a derivative (nucleoside) of purine, a precursor of adenosine triphosphate (ATP). Refers to a group of drugs that stimulate metabolic processes. Has antihypoxic, metabolic and antiarrhythmic effect. Increases the energy balance of the myocardium, improves coronary circulation, prevents the consequences of intraoperative kidney ischemia. Activates the metabolism of pyruvic acid necessary to ensure the normal process of tissue respiration, and also promotes the activation of xanthine dehydrogenase. Stimulates the synthesis of nucleotides, enhances the activity of certain enzymes of the Krebs cycle. Penetrating into cells, it has a positive effect on metabolic processes in the myocardium - it increases the strength of the heart contractions and promotes more complete relaxation of the myocardium in diastole, as a result of which the stroke volume increases. The mechanism of antiarrhythmic action is not fully understood.

Reduces the aggregation of platelets.

Pharmacokinetics:Metabolised in the liver with the formation of glucuronic acid and its subsequent oxidation. In a small amount, it is excreted by the kidneys.

Indications:

Complex treatment of myocardial infarction, ischemic heart disease of cardiac rhythm disorders caused by the use of cardiac glycosides.

Diseases of the liver (hepatitis, cirrhosis, fatty degeneration).

Operations on an isolated kidney (as a means of pharmacological protection when the circulation is turned off).

Contraindications:

Hypersensitivity to the drug, gout, hyperuricemia, pregnancy, lactation, age under 18 years (efficacy and safety not established).

Carefully:With renal failure.

Pregnancy and lactation:It is not recommended to use Riboxin during pregnancy and lactation.

Dosing and Administration:

The drug is used intravenously slowly (40-60 drops per minute) drip or jet. Treatment begins with the introduction of 200 mg (10 ml of 2% solution) once a day, then, with good tolerability, the dose is increased to 400 mg (20 ml of 2% solution) 1-2 times a day. Duration of treatment is 10-15 days.

For pharmacological protection of the kidneys subjected to ischemia, Riboxin is injected intravenously in a single dose of 1200 mg (60 ml of a 2% solution) 5-15 minutes before the clotting of the renal artery, and then 800 mg (40 ml of a 2% solution) immediately after the restoration of blood circulation .

When drip into the vein, 2% solution of the drug is diluted in a 5% solution of dextrose (glucose) or 0.9% solution of sodium chloride (up to 250 ml).

Side effects:

Allergic reactions: skin itching, skin hyperemia (drug should be discarded).

Increase in the concentration of uric acid in the blood, exacerbation of gout (with prolonged use).

Overdose:

Information on the overdose of Riboxin solution for intravenous administration of 20 mg / ml is absent.

Interaction:

When combined with cardiac glycosides, the drug can prevent the occurrence of arrhythmias, enhance the positive inotropic effect.

Special instructions:

Riboxin is not used for emergency correction of cardiac disorders.

When itching and hyperemia of the skin, treatment with the drug should be discarded.

During prolonged treatment it is desirable to control the concentration of uric acid in the blood and urine.

Form release / dosage:Solution for intravenous administration, 20 mg / ml.

Packaging:

In ampoules of 5 ml.

For 10 ampoules, together with the instructions for use and a knife for opening ampoules are placed in a pack of cardboard.

5 ampoules in a blister pack; 2 blister packs together with a knife for opening ampoules and instructions for use are put in a pack of cardboard.

10 ampoules together with a knife for opening ampoules and instructions for medical use are placed in a pack with a cardboard insert for fixing the ampoules.

In the case of ampoules with a break ring or a notch and a break point, the insertion of the knife for opening ampoules is not provided.

Storage conditions:

In the dark place at a temperature of 15 to 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after expiry date.

Terms of leave from pharmacies:On prescription

Registration number:П N015362 / 01

Date of registration:06.11.2009

The owner of the registration certificate:BORISOVSKIY FACTORY OF MEDPREPARATES, OJSC BORISOVSKIY FACTORY OF MEDPREPARATES, OJSC Republic of Belarus

Manufacturer: & nbsp

BORISOVSKIY FACTORY OF MEDPREPARATES, OJSC Republic of Belarus

Information update date: & nbsp22.10.2015

Illustrated instructions

Instructions

Riboxin (Riboxin)